388 related articles for article (PubMed ID: 25564152)
1. PEST domain mutations in Notch receptors comprise an oncogenic driver segment in triple-negative breast cancer sensitive to a γ-secretase inhibitor.
Wang K; Zhang Q; Li D; Ching K; Zhang C; Zheng X; Ozeck M; Shi S; Li X; Wang H; Rejto P; Christensen J; Olson P
Clin Cancer Res; 2015 Mar; 21(6):1487-96. PubMed ID: 25564152
[TBL] [Abstract][Full Text] [Related]
2. NOTCH-1 and NOTCH-4 are novel gene targets of PEA3 in breast cancer: novel therapeutic implications.
Clementz AG; Rogowski A; Pandya K; Miele L; Osipo C
Breast Cancer Res; 2011 Jun; 13(3):R63. PubMed ID: 21679465
[TBL] [Abstract][Full Text] [Related]
3. Discovery of biomarkers predictive of GSI response in triple-negative breast cancer and adenoid cystic carcinoma.
Stoeck A; Lejnine S; Truong A; Pan L; Wang H; Zang C; Yuan J; Ware C; MacLean J; Garrett-Engele PW; Kluk M; Laskey J; Haines BB; Moskaluk C; Zawel L; Fawell S; Gilliland G; Zhang T; Kremer BE; Knoechel B; Bernstein BE; Pear WS; Liu XS; Aster JC; Sathyanarayanan S
Cancer Discov; 2014 Oct; 4(10):1154-67. PubMed ID: 25104330
[TBL] [Abstract][Full Text] [Related]
4. Biomarker and pharmacologic evaluation of the γ-secretase inhibitor PF-03084014 in breast cancer models.
Zhang CC; Pavlicek A; Zhang Q; Lira ME; Painter CL; Yan Z; Zheng X; Lee NV; Ozeck M; Qiu M; Zong Q; Lappin PB; Wong A; Rejto PA; Smeal T; Christensen JG
Clin Cancer Res; 2012 Sep; 18(18):5008-19. PubMed ID: 22806875
[TBL] [Abstract][Full Text] [Related]
5. Evaluation of selective gamma-secretase inhibitor PF-03084014 for its antitumor efficacy and gastrointestinal safety to guide optimal clinical trial design.
Wei P; Walls M; Qiu M; Ding R; Denlinger RH; Wong A; Tsaparikos K; Jani JP; Hosea N; Sands M; Randolph S; Smeal T
Mol Cancer Ther; 2010 Jun; 9(6):1618-28. PubMed ID: 20530712
[TBL] [Abstract][Full Text] [Related]
6. Not all NOTCH Is Created Equal: The Oncogenic Role of NOTCH2 in Bladder Cancer and Its Implications for Targeted Therapy.
Hayashi T; Gust KM; Wyatt AW; Goriki A; Jäger W; Awrey S; Li N; Oo HZ; Altamirano-Dimas M; Buttyan R; Fazli L; Matsubara A; Black PC
Clin Cancer Res; 2016 Jun; 22(12):2981-92. PubMed ID: 26769750
[TBL] [Abstract][Full Text] [Related]
7. Mutational analysis of NOTCH1, 2, 3 and 4 genes in common solid cancers and acute leukemias.
Lee SH; Jeong EG; Yoo NJ; Lee SH
APMIS; 2007 Dec; 115(12):1357-63. PubMed ID: 18184405
[TBL] [Abstract][Full Text] [Related]
8. Synergistic effect of the γ-secretase inhibitor PF-03084014 and docetaxel in breast cancer models.
Zhang CC; Yan Z; Zong Q; Fang DD; Painter C; Zhang Q; Chen E; Lira ME; John-Baptiste A; Christensen JG
Stem Cells Transl Med; 2013 Mar; 2(3):233-42. PubMed ID: 23408105
[TBL] [Abstract][Full Text] [Related]
9. Gamma-secretase inhibitor prevents Notch3 activation and reduces proliferation in human lung cancers.
Konishi J; Kawaguchi KS; Vo H; Haruki N; Gonzalez A; Carbone DP; Dang TP
Cancer Res; 2007 Sep; 67(17):8051-7. PubMed ID: 17804716
[TBL] [Abstract][Full Text] [Related]
10. Nicastrin and Notch4 drive endocrine therapy resistance and epithelial to mesenchymal transition in MCF7 breast cancer cells.
Lombardo Y; Faronato M; Filipovic A; Vircillo V; Magnani L; Coombes RC
Breast Cancer Res; 2014 Jun; 16(3):R62. PubMed ID: 24919951
[TBL] [Abstract][Full Text] [Related]
11. NOTCH signaling is activated in and contributes to resistance in enzalutamide-resistant prostate cancer cells.
Farah E; Li C; Cheng L; Kong Y; Lanman NA; Pascuzzi P; Lorenz GR; Zhang Y; Ahmad N; Li L; Ratliff T; Liu X
J Biol Chem; 2019 May; 294(21):8543-8554. PubMed ID: 30940724
[TBL] [Abstract][Full Text] [Related]
12. Tumours with elevated levels of the Notch and Wnt pathways exhibit efficacy to PF-03084014, a γ-secretase inhibitor, in a preclinical colorectal explant model.
Arcaroli JJ; Quackenbush KS; Purkey A; Powell RW; Pitts TM; Bagby S; Tan AC; Cross B; McPhillips K; Song EK; Tai WM; Winn RA; Bikkavilli K; Vanscoyk M; Eckhardt SG; Messersmith WA
Br J Cancer; 2013 Aug; 109(3):667-75. PubMed ID: 23868008
[TBL] [Abstract][Full Text] [Related]
13. Ligand-dependent Notch signaling is involved in tumor initiation and tumor maintenance in pancreatic cancer.
Mullendore ME; Koorstra JB; Li YM; Offerhaus GJ; Fan X; Henderson CM; Matsui W; Eberhart CG; Maitra A; Feldmann G
Clin Cancer Res; 2009 Apr; 15(7):2291-301. PubMed ID: 19258443
[TBL] [Abstract][Full Text] [Related]
14. More Insights on the Use of γ-Secretase Inhibitors in Cancer Treatment.
López-Nieva P; González-Sánchez L; Cobos-Fernández MÁ; Córdoba R; Santos J; Fernández-Piqueras J
Oncologist; 2021 Feb; 26(2):e298-e305. PubMed ID: 33191568
[TBL] [Abstract][Full Text] [Related]
15. A high Notch pathway activation predicts response to γ secretase inhibitors in proneural subtype of glioma tumor-initiating cells.
Saito N; Fu J; Zheng S; Yao J; Wang S; Liu DD; Yuan Y; Sulman EP; Lang FF; Colman H; Verhaak RG; Yung WK; Koul D
Stem Cells; 2014 Jan; 32(1):301-12. PubMed ID: 24038660
[TBL] [Abstract][Full Text] [Related]
16. The γ-secretase inhibitor PF-03084014 combined with fludarabine antagonizes migration, invasion and angiogenesis in NOTCH1-mutated CLL cells.
López-Guerra M; Xargay-Torrent S; Rosich L; Montraveta A; Roldán J; Matas-Céspedes A; Villamor N; Aymerich M; López-Otín C; Pérez-Galán P; Roué G; Campo E; Colomer D
Leukemia; 2015 Jan; 29(1):96-106. PubMed ID: 24781018
[TBL] [Abstract][Full Text] [Related]
17. [Human diseases and NOTCH receptors].
Le Caignec C
Med Sci (Paris); 2011; 27(6-7):593-5. PubMed ID: 21718643
[No Abstract] [Full Text] [Related]
18. Gamma secretase inhibitor enhances sensitivity to doxorubicin in MDA-MB-231 cells.
Li ZL; Chen C; Yang Y; Wang C; Yang T; Yang X; Liu SC
Int J Clin Exp Pathol; 2015; 8(5):4378-87. PubMed ID: 26191129
[TBL] [Abstract][Full Text] [Related]
19. New insights into Notch1 regulation of the PI3K-AKT-mTOR1 signaling axis: targeted therapy of γ-secretase inhibitor resistant T-cell acute lymphoblastic leukemia.
Hales EC; Taub JW; Matherly LH
Cell Signal; 2014 Jan; 26(1):149-61. PubMed ID: 24140475
[TBL] [Abstract][Full Text] [Related]
20. Inhibition of gamma-secretase activity impedes uterine serous carcinoma growth in a human xenograft model.
Groeneweg JW; Hall TR; Zhang L; Kim M; Byron VF; Tambouret R; Sathayanrayanan S; Foster R; Rueda BR; Growdon WB
Gynecol Oncol; 2014 Jun; 133(3):607-15. PubMed ID: 24667249
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
